NexImmune (NEXI) Competitors $0.10 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends NEXI vs. BIOR, BDRX, PRFX, SRNE, TFFP, UPC, HSTO, TCBP, NAVB, and SMFLShould you be buying NexImmune stock or one of its competitors? The main competitors of NexImmune include Biora Therapeutics (BIOR), Biodexa Pharmaceuticals (BDRX), PainReform (PRFX), Sorrento Therapeutics (SRNE), TFF Pharmaceuticals (TFFP), Universe Pharmaceuticals (UPC), Histogen (HSTO), TC Biopharm (TCBP), Navidea Biopharmaceuticals (NAVB), and Smart for Life (SMFL). These companies are all part of the "pharmaceutical products" industry. NexImmune vs. Biora Therapeutics Biodexa Pharmaceuticals PainReform Sorrento Therapeutics TFF Pharmaceuticals Universe Pharmaceuticals Histogen TC Biopharm Navidea Biopharmaceuticals Smart for Life Biora Therapeutics (NASDAQ:BIOR) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking, media sentiment and dividends. Which has preferable earnings & valuation, BIOR or NEXI? NexImmune has lower revenue, but higher earnings than Biora Therapeutics. Biora Therapeutics is trading at a lower price-to-earnings ratio than NexImmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiora Therapeutics$892K0.61-$124.11M-$13.04-0.01NexImmuneN/AN/A-$32.34M-$18.54-0.01 Does the media refer more to BIOR or NEXI? In the previous week, Biora Therapeutics' average media sentiment score of 0.00 equaled NexImmune'saverage media sentiment score. Company Overall Sentiment Biora Therapeutics Neutral NexImmune Neutral Is BIOR or NEXI more profitable? Biora Therapeutics' return on equity of 0.00% beat NexImmune's return on equity.Company Net Margins Return on Equity Return on Assets Biora TherapeuticsN/A N/A -332.47% NexImmune N/A -534.32%-213.72% Does the MarketBeat Community prefer BIOR or NEXI? NexImmune received 14 more outperform votes than Biora Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Biora Therapeutics an outperform vote while only 61.11% of users gave NexImmune an outperform vote. CompanyUnderperformOutperformBiora TherapeuticsOutperform Votes880.00% Underperform Votes220.00% NexImmuneOutperform Votes2261.11% Underperform Votes1438.89% Which has more volatility and risk, BIOR or NEXI? Biora Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, NexImmune has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Do analysts recommend BIOR or NEXI? Biora Therapeutics presently has a consensus target price of $23.00, indicating a potential upside of 19,066.67%. Given Biora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Biora Therapeutics is more favorable than NexImmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biora Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NexImmune 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of BIOR or NEXI? 43.7% of Biora Therapeutics shares are held by institutional investors. Comparatively, 9.9% of NexImmune shares are held by institutional investors. 51.1% of Biora Therapeutics shares are held by insiders. Comparatively, 14.9% of NexImmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryBiora Therapeutics beats NexImmune on 9 of the 14 factors compared between the two stocks. Get NexImmune News Delivered to You Automatically Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEXI vs. The Competition Export to ExcelMetricNexImmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$139,000.00$7.05B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.015.9726.4919.17Price / SalesN/A268.58435.3770.93Price / CashN/A65.6738.0134.83Price / Book0.036.707.644.62Net Income-$32.34M$138.76M$3.19B$246.06M7 Day PerformanceN/A-2.63%-2.12%-2.63%1 Month PerformanceN/A-2.33%-0.45%-2.16%1 Year PerformanceN/A-5.33%16.26%12.88% NexImmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEXINexImmuneN/A$0.10flatN/AN/A$139,000.00N/A-0.016BIORBiora Therapeutics1.9949 of 5 stars$0.12-22.0%$23.00+18,675.5%-98.5%$554,000.00$892,000.00-0.01120Gap DownBDRXBiodexa Pharmaceuticals0.7149 of 5 stars$4.27-11.8%N/AN/A$512,000.00$470,000.000.0020Gap DownHigh Trading VolumePRFXPainReform1.9988 of 5 stars$2.82-2.8%$8.00+183.7%-60.5%$395,000.00N/A-0.024Negative NewsGap DownSRNESorrento TherapeuticsN/A$0.00-84.2%N/A-98.1%$331,000.00$62.84M0.00800Analyst ForecastGap DownTFFPTFF Pharmaceuticals1.2876 of 5 stars$0.07flat$44.00+67,592.3%N/A$289,000.00$730,000.00-0.0119High Trading VolumeUPCUniverse PharmaceuticalsN/A$0.17-0.6%N/A-99.2%$283,000.00$26.73M0.00220Gap DownHSTOHistogenN/A$0.03-5.9%N/A-93.3%$115,000.00$19,000.00-0.0120Gap DownHigh Trading VolumeTCBPTC Biopharm2.0244 of 5 stars$2.44-0.8%$48.00+1,867.2%-98.6%$81,000.00$4.76M0.0080Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00+16.7%N/A-98.3%$70,000.00$8,126.000.0010Analyst ForecastSMFLSmart for LifeN/A$0.01-9.5%N/A-99.9%$67,000.00$11.11M0.00110Gap Down Related Companies and Tools Related Companies Biora Therapeutics Competitors Biodexa Pharmaceuticals Competitors PainReform Competitors Sorrento Therapeutics Competitors TFF Pharmaceuticals Competitors Universe Pharmaceuticals Competitors Histogen Competitors TC Biopharm Competitors Navidea Biopharmaceuticals Competitors Smart for Life Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NEXI) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
